Literature DB >> 12014651

Hyperthermia increases the susceptibility of chondro- and osteosarcoma cells to natural killer cell-mediated lysis.

B Kubista1, K Trieb, H Blahovec, R Kotz, M Micksche.   

Abstract

As an adjuvant to chemotherapy hyperthermia has proven to be successful as a treatment for osteo- and chondrosarcoma patients. The aim of this study was to investigate whether hyperthermia could increase cellular expression of heat-shock-protein 72 in human osteo- and chondrosarcoma cells and how heat treatment would affect their susceptibility to natural killer cell (NK-cell)-mediated lysis. About 5-10% of the peripheral mononuclear blood cells (PBMC) in the human peripheral blood are natural killer cells (NK-cells). Natural cytotoxicity, mediated by NK-cells, is believed to play an important role in host defense against cancer. The exact mechanisms of recognition of target cells and subsequent NK-cell activation are not yet known. NK-cells, isolated from the peripheral blood of healthy donors, were enriched by magnetic cell-separation to a purity of 85-97%, assessed by FACS-analysis. The susceptibility of heat-treated (42.5 degrees C, 90 minutes) and untreated osteosarcoma (MG63) and chondrosarcoma (HTB94) cell lines to NK-killing was determined by a release assay of lactate dehydrogenase (LDH). Lysis by NK-cells was increased by heat treatment of the target cells from 16.6% + 4.5% to 33% + 15%, p=0.035, for osteosarcoma cells, (E/T ratio of 5:1) and from 13.7% + 3.1% to 27.9% + 16.9%, p=0.021, (E/T ratio of 20:1) for chondrosarcoma cells. An increased expression of HSP72 of chondro- and osteosarcoma cells after heat treatment was detected by the Western blot technique. The results of this study show that hyperthermia increases HSP72 expression in osteo- and chondrosarcoma cells and their susceptibility to NK-cell-mediated lysis. These findings may lead to new therapeutic strategies, using hyperthermia to improve immunological defense against chondro- and osteosarcoma cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12014651

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  Cytotoxicity of activated natural killer cells against pediatric solid tumors.

Authors:  Duck Cho; David R Shook; Noriko Shimasaki; Yu-Hsiang Chang; Hiroyuki Fujisaki; Dario Campana
Journal:  Clin Cancer Res       Date:  2010-06-11       Impact factor: 12.531

2.  Cryoimmunologic antitumor effects enhanced by dendritic cells in osteosarcoma.

Authors:  Masanori Kawano; Hideji Nishida; Yasunari Nakamoto; Hiroshi Tsumura; Hiroyuki Tsuchiya
Journal:  Clin Orthop Relat Res       Date:  2010-03-16       Impact factor: 4.176

Review 3.  Natural Killer Cell Immunotherapy for Osteosarcoma.

Authors:  Brian P Tullius; Buhvana A Setty; Dean A Lee
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

4.  Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells.

Authors:  Emilie P Buddingh; Marco W Schilham; S Eriaty N Ruslan; Dagmar Berghuis; Karoly Szuhai; Jolien Suurmond; Antonie H M Taminiau; Hans Gelderblom; R Maarten Egeler; Massimo Serra; Pancras C W Hogendoorn; Arjan C Lankester
Journal:  Cancer Immunol Immunother       Date:  2011-01-15       Impact factor: 6.968

5.  In Vivo Imaging of Local Gene Expression Induced by Magnetic Hyperthermia.

Authors:  Olivier Sandre; Coralie Genevois; Eneko Garaio; Laurent Adumeau; Stéphane Mornet; Franck Couillaud
Journal:  Genes (Basel)       Date:  2017-02-08       Impact factor: 4.096

Review 6.  Prospects for NK Cell Therapy of Sarcoma.

Authors:  Mieszko Lachota; Marianna Vincenti; Magdalena Winiarska; Kjetil Boye; Radosław Zagożdżon; Karl-Johan Malmberg
Journal:  Cancers (Basel)       Date:  2020-12-11       Impact factor: 6.639

7.  Development of a novel immune-related genes prognostic signature for osteosarcoma.

Authors:  Zuo-Long Wu; Ya-Jun Deng; Guang-Zhi Zhang; En-Hui Ren; Wen-Hua Yuan; Qi-Qi Xie
Journal:  Sci Rep       Date:  2020-10-27       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.